aspen: zanubrutinib vs ibrutinib in waldenström's macroglobulinemia
Published 4 years ago • 259 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
6:05
aspen: zanubrutinib versus ibrutinib in patients with wm
-
1:44
the efficacy of zanubrutinib versus ibrutinib in patients with wm harboring various mutations
-
1:09
assessing cardiovascular tolerability of zanubrutinib vs ibrutinib in pts with b-cell malignancies
-
5:20
constantine tam: comparing zanubrutinib with ibrutinib in waldenström macroglobulinemia
-
4:15
zanubrutinib versus rituximab-based chemoimmunotherapy in waldenström's macroglobulinemia
-
3:54
aspen trial: zanubrutinib versus ibrutinib for patients with waldenström macroglobulinemia
-
4:39
expanded access study of zanubrutinib in patients with waldenström’s macroglobulinemia
-
1:55
the alpine trial shows improved outcomes with zanubrutinib versus ibrutinib in r/r cll
-
7:37
living with waldenstrom's with bob rupert
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
6:42
diffuse large b-cell lymphoma - diagnosis& treatment - aggressive b-cell non-hodgkin’s lymphoma
-
3:48
impressive data: zanubrutinib for waldenström’s macroglobulinemia
-
1:29
insights into the uses of ibrutinib for patients with waldenström’s macroglobulinemia
-
35:47
zanubrutinib for the treatment of waldenstrom's macroglobulinemia
-
4:33
brawm: bendamustine, rituximab and acalabrutinib for waldenström’s macroglobulinemia
-
1:00
ash 2022 lba: results from final analysis of alpine - zanubrutinib vs ibrutinib for r/r cll/sll
-
1:13
alpine trial update: zanubrutinib continues to show superior efficacy to ibrutinib in cll
-
3:28
biology of waldenström macroglobulinemia
-
3:03
long-term follow-up of ibrutinib in waldenström's macroglobulinemia
-
1:42
dr. flinn on the innovate trial in waldenstrom macroglobulinemia
-
1:01
the value of genomics in waldenström’s macroglobulinemia
-
45:34
timely updates in the treatment of waldenstrom's macroglobulinemia-zanubrutinib